Rangiferine Brucellosis in a Muskox, Ovibos moschatus moschatus (Zimmermann)

C. Gates,G. Wobeser,L. Forbes

DOI: https://doi.org/10.7589/0090-3558-20.3.233

1984-07-01

Journal of Wildlife Diseases

Abstract:

What problem does this paper attempt to address?

Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT)

Saeed Farooq,Miriam Hattle,Tom Kingstone,Olesya Ajnakina,Paola Dazzan,Arsime Demjaha,Robin M Murray,Marta Di Forti,Peter B Jones,Gillian A Doody,David Shiers,Gabrielle Andrews,Abbie Milner,Maria Antonietta Nettis,Andrew J Lawrence,Danielle A van der Windt,Richard D Riley

DOI: https://doi.org/10.1192/bjp.2024.101

2024-08-05

Abstract:Background: A clinical tool to estimate the risk of treatment-resistant schizophrenia (TRS) in people with first-episode psychosis (FEP) would inform early detection of TRS and overcome the delay of up to 5 years in starting TRS medication. Aims: To develop and evaluate a model that could predict the risk of TRS in routine clinical practice. Method: We used data from two UK-based FEP cohorts (GAP and AESOP-10) to develop and internally validate a prognostic model that supports identification of patients at high-risk of TRS soon after FEP diagnosis. Using sociodemographic and clinical predictors, a model for predicting risk of TRS was developed based on penalised logistic regression, with missing data handled using multiple imputation. Internal validation was undertaken via bootstrapping, obtaining optimism-adjusted estimates of the model's performance. Interviews and focus groups with clinicians were conducted to establish clinically relevant risk thresholds and understand the acceptability and perceived utility of the model. Results: We included seven factors in the prediction model that are predominantly assessed in clinical practice in patients with FEP. The model predicted treatment resistance among the 1081 patients with reasonable accuracy; the model's C-statistic was 0.727 (95% CI 0.723-0.732) prior to shrinkage and 0.687 after adjustment for optimism. Calibration was good (expected/observed ratio: 0.999; calibration-in-the-large: 0.000584) after adjustment for optimism. Conclusions: We developed and internally validated a prediction model with reasonably good predictive metrics. Clinicians, patients and carers were involved in the development process. External validation of the tool is needed followed by co-design methodology to support implementation in early intervention services.
Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

Sophie E. Smart,Deborah Agbedjro,Antonio F. Pardiñas,Olesya Ajnakina,Luis Alameda,Ole A. Andreassen,Thomas R.E. Barnes,Domenico Berardi,Sara Camporesi,Martine Cleusix,Philippe Conus,Benedicto Crespo-Facorro,Giuseppe D'Andrea,Arsime Demjaha,Marta Di Forti,Kim Do,Gillian Doody,Chin B. Eap,Aziz Ferchiou,Lorenzo Guidi,Lina Homman,Raoul Jenni,Eileen Joyce,Laura Kassoumeri,Ornella Lastrina,Ingrid Melle,Craig Morgan,Francis A. O'Neill,Baptiste Pignon,Romeo Restellini,Jean-Romain Richard,Carmen Simonsen,Filip Španiel,Andrei Szöke,Ilaria Tarricone,Andrea Tortelli,Alp Üçok,Javier Vázquez-Bourgon,Robin M. Murray,James T.R. Walters,Daniel Stahl,James H. MacCabe

DOI: https://doi.org/10.1016/j.schres.2022.09.009

IF: 4.662

2022-10-13

Schizophrenia Research

Abstract:Introduction Our aim was to, firstly, identify characteristics at first-episode of psychosis that are associated with later antipsychotic treatment resistance (TR) and, secondly, to develop a parsimonious prediction model for TR. Methods We combined data from ten prospective, first-episode psychosis cohorts from across Europe and categorised patients as TR or non-treatment resistant (NTR) after a mean follow up of 4.18 years (s.d. = 3.20) for secondary data analysis. We identified a list of potential predictors from clinical and demographic data recorded at first-episode. These potential predictors were entered in two models: a multivariable logistic regression to identify which were independently associated with TR and a penalised logistic regression, which performed variable selection, to produce a parsimonious prediction model. This model was internally validated using a 5-fold, 50-repeat cross-validation optimism-correction. Results Our sample consisted of N = 2216 participants of which 385 (17 %) developed TR. Younger age of psychosis onset and fewer years in education were independently associated with increased odds of developing TR. The prediction model selected 7 out of 17 variables that, when combined, could quantify the risk of being TR better than chance. These included age of onset, years in education, gender, BMI, relationship status, alcohol use, and positive symptoms. The optimism-corrected area under the curve was 0.59 (accuracy = 64 %, sensitivity = 48 %, and specificity = 76 %). Implications Our findings show that treatment resistance can be predicted, at first-episode of psychosis. Pending a model update and external validation, we demonstrate the potential value of prediction models for TR.

psychiatry
A predictor model of treatment resistance in schizophrenia using data from electronic health records

Giouliana Kadra-Scalzo,Daniela Fonseca de Freitas,Deborah Agbedjro,Emma Francis,Isobel Ridler,Megan Pritchard,Hitesh Shetty,Aviv Segev,Cecilia Casetta,Sophie E. Smart,Anna Morris,Johnny Downs,Søren Rahn Christensen,Nikolaj Bak,Bruce J. Kinon,Daniel Stahl,Richard D. Hayes,James H. MacCabe

DOI: https://doi.org/10.1371/journal.pone.0274864

IF: 3.7

2022-09-20

PLoS ONE

Abstract:To develop a prognostic tool of treatment resistant schizophrenia (TRS) in a large and diverse clinical cohort, with comprehensive coverage of patients using mental health services in four London boroughs. We used the Least Absolute Shrinkage and Selection Operator (LASSO) for time-to-event data, to develop a risk prediction model from the first antipsychotic prescription to the development of TRS, using data from electronic health records. We reviewed the clinical records of 1,515 patients with a schizophrenia spectrum disorder and observed that 253 (17%) developed TRS. The Cox LASSO survival model produced an internally validated Harrel's C index of 0.60. A Kaplan-Meier curve indicated that the hazard of developing TRS remained constant over the observation period. Predictors of TRS were: having more inpatient days in the three months before and after the first antipsychotic, more community face-to-face clinical contact in the three months before the first antipsychotic, minor cognitive problems, and younger age at the time of the first antipsychotic. Routinely collected information, readily available at the start of treatment, gives some indication of TRS but is unlikely to be adequate alone. These results provide further evidence that earlier onset is a risk factor for TRS.

multidisciplinary sciences
Early Treatment-Resistance in First Episode Psychosis

Piyumi Fernando,Johanna Strauss,Elias Wagner,Lisa Löhrs,Mattia Campana,Peter Falkai,Alkomiet Hasan,Irina Papazova

DOI: https://doi.org/10.1055/a-2421-2411

2024-11-23

Pharmacopsychiatry

Abstract:Introduction Approximately 30% of individuals with schizophrenia experience treatment resistance (TR), with 70% exhibiting it from the onset. Most research fails to distinguish between acquired and innate resistance, with limited data on TR in first episode psychosis (FEP). However, FEP patients with TR experience progressively worse outcomes compared to those with initial response. To further understand these findings, clinical and demographic data of FEP patients with and without TR were compared in this naturalistic study. Methods Information was extracted on FEP patients who were antipsychotic-naive at the time of admission from a retrospective database on F2x diagnosed patients admitted to the LMU psychiatric clinic between 2008 and 2018. Clozapine was used at discharge as a marker of TR in the FEP cohort. A similarly antipsychotic-naïve FEP control group without clozapine at discharge, was generated by matching for gender and age. Thirty clinical and demographic variables were analyzed to identify differences. Results Two-hundred forty antipsychotic-naive FEPs were included: 33 with clozapine at discharge (TRC group), and 207 in the control group (non-TRC). Significant differences were observed in inpatient stay duration, chlorpromazine-equivalent dosage, number of antipsychotics, and anticholinergic medication at discharge. Discussion The findings indicate that longer inpatient stay, an increased number of antipsychotics, and possibly a more extended prodrome may serve as markers for non-clozapine TR in FEP. Further research is necessary to establish the robustness of these variables as early-stage TR markers. Received: 26 February 2024 Received: 05 August 2024 Accepted: 16 September 2024 Article published online: 15 November 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

pharmacology & pharmacy,psychiatry
Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition

Yanhui Li,Mei San Ang,Jie Yin Yee,Yuen Mei See,Jimmy Lee

DOI: https://doi.org/10.3389/fpsyt.2024.1444843

2024-08-23

Abstract:Introduction: Predictors of functioning are well-studied in schizophrenia, but much less so in treatment-resistant schizophrenia (TRS). In this study, we aim to investigate contributions of schizophrenia symptom domains and neurocognition to predict functioning in a TRS population (n = 146). Methods: Participants were assessed on the Positive and Negative Syndrome Scale (PANSS), to calculate scores for five symptom factors (Positive, Negative, Cognitive, Depressive and Hostility) and two negative symptom constructs (Diminished Expressivity (DE), and Social Anhedonia (SA) as part of the Motivation and Pleasure-related dimension), based on a previously validated model, modified in accordance with EPA guidelines on negative symptoms assessment. Neurocognition was assessed with symbol coding and digit sequencing tasks from the Brief Assessment of Cognition in Schizophrenia (BACS). Functioning was assessed with the Social and Occupational Functioning Assessment Scale (SOFAS), employment status and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). Multiple regression analyses were performed on psychopathology scores and BACS scores against all three measures of functioning, controlling for age and sex. For WHODAS, regression with PANSS scores of significant symptom factors were also performed. Results: A lower severity of negative symptoms in the SA dimension was the strongest predictor of higher functioning across all three functioning measures. Neurocognition, in particular processing speed and attention assessed on the symbol coding task, predicted employment. A lower severity of somatic concerns and depressive symptoms was associated with lesser self-reported disability on WHODAS. Discussion: This study represents a first attempt at elucidating significant predictors of functioning in TRS. We highlight negative symptoms and neurocognition as important treatment targets to improve functioning in TRS, consistent with previous studies in general schizophrenia.
Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates

Mirza Detanac,Chelsey Williams,Milan Dragovic,Gordon Shymko,Alexander Panickacheril John

DOI: https://doi.org/10.1177/00048674241274314

2024-09-01

Australian & New Zealand Journal of Psychiatry

Abstract:Australian &New Zealand Journal of Psychiatry, Ahead of Print. Objective:The prevalence of treatment-resistant schizophrenia (TRS) among people with first-episode schizophrenia (FES) has been sub-optimally researched in Australia and internationally. We evaluated the prevalence of TRS among a cohort of FES patients and compared their sociodemographic and clinical characteristics to those with FES who were treatment responsive.Methods:Over 2 years, we collated demographic, clinical and treatment-related data of all patients with ICD-10 (International Classification of Diseases, Tenth revision) diagnosis of schizophrenia who were active in October 2020 at four early psychosis intervention services (EPIS) in Western Australia. We used a modified version of Suzuki et al. criteria to diagnose TRS. The data were analysed utilising descriptive statistics, the Mann–Whitney U test, Student's t-test and the False-Discovery Rate method.Results:The prevalence of TRS among the 167 patients diagnosed with FES was 41.3%, and the rates did not differ significantly between the services (p = 0.955). Those in the TRS group were less independent (p = 0.011), had more prolonged unemployment (p = 0.014) and were more likely to be on disability pension (p = 0.011) compared to the treatment responsive group. Furthermore, they had greater severity of symptoms (p = 0.002), longer duration of psychiatric symptoms (p = 0.019), more hospitalisations (p = 0.002) and longer cumulative admission durations (p = 0.002).Conclusions:Our study revealed that treatment resistance to antipsychotics is prevalent among people with FES managed at EPIS. Notably, it establishes an association between TRS and heightened clinical severity and psychosocial and treatment burden. These findings highlight the imperative for early detection of treatment resistance and timely and specialised interventions for this condition in mental health services.

psychiatry
Apoptosis, necrosis and autophagy: from mechanisms to biomedical applications.

C. Hetz

Current Molecular Medicine

Abstract:
Neurodevelopmental predictors of treatment response in schizophrenia and bipolar disorder

Anton Iftimovici,Emma Krebs,William Dalfin,Adrien Legrand,Linda Scoriels,Gilles Martinez,Narjes Bendjemaa,Edouard Duchesnay,Boris Chaumette,Marie-Odile Krebs

DOI: https://doi.org/10.1017/s0033291724001776

IF: 10.592

2024-10-17

Psychological Medicine

Abstract:Background Treatment resistance is a major challenge in psychiatric disorders. Early detection of potential future resistance would improve prognosis by reducing the delay to appropriate treatment adjustment and recovery. Here, we sought to determine whether neurodevelopmental markers can predict therapeutic response. Methods Healthy controls (N = 236), patients with schizophrenia (N = 280) or bipolar disorder (N = 78) with a known therapeutic outcome, were retrospectively included. Age, sex, education, early developmental abnormalities (obstetric complications, height, weight, and head circumference at birth, hyperactivity, dyslexia, epilepsy, enuresis, encopresis), neurological soft signs (NSS), and ages at first subjective impairment, clinical symptoms, treatment, and hospitalization, were recorded. A supervised algorithm leveraged NSS and age at first clinical signs to classify between resistance and response in schizophrenia. Results Developmental abnormalities were more frequent in schizophrenia and bipolar disorder than in controls. NSS significantly differed between controls, responsive, and resistant participants with schizophrenia (5.5 ± 3.0, 7.0 ± 4.0, 15.0 ± 6.0 respectively, p = 3 × 10 −10 ) and bipolar disorder (5.5 ± 3.0, 8.3 ± 3.0, 12.5 ± 6.0 respectively, p < 1 × 10 −10 ). In schizophrenia, but not in bipolar disorder, age at first subjective impairment was three years lower, and age at first clinical signs two years lower, in resistant than responsive subjects (p = 2 × 10 −4 and p = 9 × 10 −3 , respectively). Age at first clinical signs and NSS accurately predicted treatment response in schizophrenia (area-under-curve: 77 ± 8%, p = 1 × 10 −14 ). Conclusions Neurodevelopmental features such as NSS and age of clinical onset provide a means to identify patients who may require rapid treatment adaptation.

psychiatry,psychology, clinical
Development of an individualized risk calculator of treatment resistance in patients with first-episode psychosis (TRipCal) using automated machine learning: a 12-year follow-up study with clozapine prescription as a proxy indicator

Ting Yat Wong,Hao Luo,Jennifer Tang,Tyler M. Moore,Ruben C. Gur,Yi Nam Suen,Christy Lai Ming Hui,Edwin Ho Ming Lee,Wing Chung Chang,Wai Ching Yan,Eileena Chui,Lap Tak Poon,Alison Lo,Koi-Man Cheung,Chui Kwan Kan,Eric Yu Hai Chen,Sherry Kit Wa Chan

DOI: https://doi.org/10.1038/s41398-024-02754-w

2024-01-23

Translational Psychiatry

Abstract:About 15–40% of patients with schizophrenia are treatment resistance (TR) and require clozapine. Identifying individuals who have higher risk of development of TR early in the course of illness is important to provide personalized intervention. A total of 1400 patients with FEP enrolled in the early intervention for psychosis service or receiving the standard psychiatric service between July 1, 1998, and June 30, 2003, for the first time were included. Clozapine prescriptions until June 2015, as a proxy of TR, were obtained. Premorbid information, baseline characteristics, and monthly clinical information were retrieved systematically from the electronic clinical management system (CMS). Training and testing samples were established with random subsampling. An automated machine learning (autoML) approach was used to optimize the ML algorithm and hyperparameters selection to establish four probabilistic classification models (baseline, 12-month, 24-month, and 36-month information) of TR development. This study found 191 FEP patients (13.7%) who had ever been prescribed clozapine over the follow-up periods. The ML pipelines identified with autoML had an area under the receiver operating characteristic curve ranging from 0.676 (baseline information) to 0.774 (36-month information) in predicting future TR. Features of baseline information, including schizophrenia diagnosis and age of onset, and longitudinal clinical information including symptoms variability, relapse, and use of antipsychotics and anticholinergic medications were important predictors and were included in the risk calculator. The risk calculator for future TR development in FEP patients (TRipCal) developed in this study could support the continuous development of data-driven clinical tools to assist personalized interventions to prevent or postpone TR development in the early course of illness and reduce delay in clozapine initiation.

psychiatry
Subtyping First-Episode Psychosis based on Longitudinal Symptom Trajectories Using Machine Learning

Yanan Liu,Sara Jalali,Ridha Joober,Martin Lepage,Srividya Iyer,Jai Shah,David Benrimoh

DOI: https://doi.org/10.1101/2024.09.17.24313827

2024-09-18

Abstract:Clinical course after first episode psychosis (FEP) is heterogeneous. Subgrouping longitudinal symptom trajectories after FEP would be useful for developing personalized treatment approaches, and being able to predict these trajectories at baseline would facilitate individual-level treatment planning. We utilized k-means clustering to identify distinct clusters of 411 FEP patients based on longitudinal positive and negative symptom patterns. Ridge logistic regression was then used to identify predictors of cluster membership using baseline data. Three clusters were identified, demonstrating unique demographic, clinical and treatment response profiles. Cluster 1 exhibits lower positive and negative symptoms (LS), lower antipsychotic dose, and relatively higher affective psychosis; Cluster 2 shows lower positive symptoms, persistent negative symptoms (LPPN), and intermediate antipsychotic doses; Cluster 3 presents persistently high levels of both positive and negative symptoms (PPNS), as well as higher antipsychotic doses. We effectively predicted patients' cluster membership (AUC of 0.74). The most important predictive features included contrasting trends of apathy, affective flattening, and anhedonia for the LS and LPPN clusters. Global hallucination severity, positive thought disorder and manic hostility predicted PPNS. These results help parse the heterogeneity of FEP trajectories and may facilitate the development of personalized treatment approaches tailored to cluster characteristics.

Psychiatry and Clinical Psychology
Long-term clinical recovery and treatment resistance in first-episode psychosis: a 10-year follow-up study

Kristin Fjelnseth Wold,Isabel Viola Kreis,Gina Åsbø,Camilla Bärthel Flaaten,Line Widing,Magnus Johan Engen,Siv Hege Lyngstad,Erik Johnsen,Torill Ueland,Carmen Simonsen,Ingrid Melle

DOI: https://doi.org/10.1038/s41537-024-00489-7

2024-08-22

Abstract:Illness trajectories in people with first-episode psychosis (FEP) vary significantly over time. Identifying early-course parameters predicting outcomes is essential, but long-term data still needs to be provided. We conducted a 10-year follow-up study of a comprehensive first-episode psychosis (FEP) cohort investigating the prevalence of clinical recovery (CR) and treatment resistance (TR) after ten years, as well as clinical, demographic, and pre-illness predictors of long-term outcomes. 102 participants with FEP DSM-IV Schizophrenia spectrum disorders were recruited within their first year of treatment. The Treatment Response and Resistance in Psychosis Working Group (TRRIP) and the Remission in Schizophrenia Working Group (RSWG) criteria were used to define TR and CR, respectively. At 10-year follow-up, 29 (29%) of the participants were classified as in CR, while 32 (31%) were classified as TR. We also identified a larger middle group (n = 41, 40%) consisting of participants in partial recovery. 7% of all participants had tried Clozapine at the 10-year follow-up. Logistic regression analyses identified insidious onset (OR = 4.16) and baseline disorganized symptoms (OR = 2.96) as significantly associated with an increased risk of developing TR. Good premorbid academic adjustment (OR = 1.60) and acute onset (OR = 3.40) were associated with an increased chance of CR. We identified three long-term outcome groups by using recent consensus definitions. We also identified the potential importance of assessing baseline disorganized symptoms and monitoring patients with insidious onset more closely. Further, the findings suggest that clinicians should pay close attention to early-course parameters and provide adequate treatment to improve long-term outcomes of FEP.
Different Lifestyles and their Impact on the Environment

P. Christensen

DOI: https://doi.org/10.1002/(SICI)1099-1719(199703)5:1<30::AID-SD59>3.0.CO;2-5

1997-03-01

Abstract:The transition to a sustainable society is happening too slowly. Although many changes have been introduced in public policies to ensure the greening of industry, these steps towards sustainability are insufficient unless individual households also contribute. This study tries to show that households have very different impacts on the environment. A difference in lifestyle, i.e. how we choose to live, be transported and choose our provisions, can have a dramatic impact on the environment. Based on life cycle assessment the environmental impacts from cradle to grave of different lifestyles have been calculated. The study shows that there are large differences among the analysed families. The 'American lifestyle 'family, which is very dependent on transport by car, lives in its own large house and eats a lot of meat, pollutes eight times as much as the analysed 'green' family. The study thus demonstrates that it is necessary to influence lifestyles as a logical next step in the transition to a sustainable society. © 1997 by John Wiley & Sons, Ltd. and ERP Environment Sustainable Development, Vol. 5, 30-35 (1997)
Tracking Positive and Negative Symptom Improvement in First-Episode Schizophrenia Treated with Risperidone Using Individual-Level Functional Connectivity

Yun-Shuang Fan,Haoru Li,Jing Guo,Yajing Pang,Liang Li,Maolin Hu,Meiling Li,Chong Wang,Wei Sheng,Hesheng Liu,Qing Gao,Xiaogang Chen,Xiaofen Zong,Huafu Chen

DOI: https://doi.org/10.1089/brain.2021.0061

2021-01-01

Brain Connectivity

Abstract:Background: To improve treatment outcomes of patients with schizophrenia, research efforts have focused on identifying brain-based markers of treatment response. Personal characteristics regarding disease-related behaviors likely stem from interindividual variability in the organization of brain functional systems. This study aimed to track dimension-specific changes in psychotic symptoms following risperidone treatment using individual-level functional connectivity (FC). Methods: A reliable cortical parcellation approach that accounts for individual heterogeneity in cortical functional anatomy was used to localize functional regions in a longitudinal cohort consisting of 42, drug-naive, first-episode schizophrenia (FES) patients at baseline and after 8 weeks of risperidone treatment. FC was calculated in individually specified brain regions and used to predict the baseline severity and improvement of positive and negative symptoms in FES. Results: Distinct sets of individual-specific FC were separately associated with the positive and negative symptom burden at baseline, which could be used to track the corresponding symptom resolution in FES patients following risperidone treatment. Between-network connections of the fronto-parietal network (FPN) contributed the most to predicting the positive symptom domain. A combination of between-network connections of the default mode network, FPN, and within-network connections of the FPN contributed markedly to the prediction model of negative symptoms. Conclusion: This novel study, which accounts for individual brain variation, takes a step toward establishing individual-specific theranostic biomarkers in schizophrenia. Impact statement This study revealed a theranostic marker for personalized medicine in schizophrenia and may aid in circuit-specific therapies for this disorder.
Psychosis Prognosis Predictor: A continuous and uncertainty‐aware prediction of treatment outcome in first‐episode psychosis

Daniël P. J. van Opstal,Seyed Mostafa Kia,Lea Jakob,Metten Somers,Iris E. C. Sommer,Inge Winter‐van Rossum,René S. Kahn,Wiepke Cahn,Hugo G. Schnack

DOI: https://doi.org/10.1111/acps.13754

2024-09-20

Acta Psychiatrica Scandinavica

Abstract:Introduction Machine learning models have shown promising potential in individual‐level outcome prediction for patients with psychosis, but also have several limitations. To address some of these limitations, we present a model that predicts multiple outcomes, based on longitudinal patient data, while integrating prediction uncertainty to facilitate more reliable clinical decision‐making. Material and Methods We devised a recurrent neural network architecture incorporating long short‐term memory (LSTM) units to facilitate outcome prediction by leveraging multimodal baseline variables and clinical data collected at multiple time points. To account for model uncertainty, we employed a novel fuzzy logic approach to integrate the level of uncertainty into individual predictions. We predicted antipsychotic treatment outcomes in 446 first‐episode psychosis patients in the OPTiMiSE study, for six different clinical scenarios. The treatment outcome measures assessed at both week 4 and week 10 encompassed symptomatic remission, clinical global remission, and functional remission. Results Using only baseline predictors to predict different outcomes at week 4, leave‐one‐site‐out validation AUC ranged from 0.62 to 0.66; performance improved when clinical data from week 1 was added (AUC = 0.66–0.71). For outcome at week 10, using only baseline variables, the models achieved AUC = 0.56–0.64; using data from more time points (weeks 1, 4, and 6) improved the performance to AUC = 0.72–0.74. After incorporating prediction uncertainties and stratifying the model decisions based on model confidence, we could achieve accuracies above 0.8 for ~50% of patients in five out of the six clinical scenarios. Conclusion We constructed prediction models utilizing a recurrent neural network architecture tailored to clinical scenarios derived from a time series dataset. One crucial aspect we incorporated was the consideration of uncertainty in individual predictions, which enhances the reliability of decision‐making based on the model's output. We provided evidence showcasing the significance of leveraging time series data for achieving more accurate treatment outcome prediction in the field of psychiatry.

psychiatry
Association of U2, U4, U5, and U6 small nuclear ribonucleoproteins in a spliceosome-type complex in absence of precursor RNA.

M. Konarska,P. Sharp

DOI: https://doi.org/10.1073/PNAS.85.15.5459

1988-08-01

Abstract:Small nuclear ribonucleoprotein particles (snRNPs) associate to form multi-snRNP complexes during splicing of mRNA precursors. A vast majority of the three snRNPs U4, U5, and U6 are present in a nuclear extract in a single complex, while U1 and U2 snRNPs exist as separate particles. Under conditions optimal for splicing in vitro the U4-U5-U6 (U4/5/6) complex dissociates to release free snRNPs, suggesting that the interactions between its components are dynamic. Several forms of splicing complexes assemble on precursor RNA during splicing in vitro. One of these forms, spliceosome B, contains U2, U4, U5, and U6 snRNPs bound to the precursor RNA. This same set of snRNPs associates efficiently in the absence of precursor RNA during incubation of the extract at high salt concentration. Formation of this U2-U4-U5-U6 (U2/4/5/6) complex, the pseudospliceosome, suggests that the basic structure of the spliceosome is specified by snRNP-snRNP interactions.
Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care

Joshua N Liberman,Tigwa Davis,Jacqui Pesa,Wing Chow,John Verbanac,Sara Heverly-Fitt,Charles Ruetsch

DOI: https://doi.org/10.18553/jmcp.2020.26.8.987

Abstract:Background: Major depressive disorder (MDD) is a prevalent and debilitating condition. While numerous treatment options are available, low treatment response and high remission rates remain common, leading to the concept of treatment-resistant depression (TRD): a classification applied to patients who fail multiple courses of therapy. A patient with TRD can only be identified after repeated, and often prolonged, therapeutic efforts. Objective: To use data readily available to integrated delivery networks to identify characteristics predictive of TRD among patients initiating pharmacotherapy for MDD. Methods: Decision Resources Group Real-World Data, an integrated medical/pharmacy claims and electronic health record dataset, was used to conduct a retrospective, longitudinal cohort study of patients with MDD who initiated antidepressant treatment between July 1, 2014, and December 31, 2015. Individuals were followed for 24 months to determine treatment resistance. Eligible individuals had integrated claims and electronic health record data available, completed at least 1 course of therapy of adequate dose and duration to achieve response, and had 30 months of continuous benefits eligibility (6 months before and 24 months after treatment initiation). Stepwise logistic regression and demographic, health history, health care utilization, medication, provider, and related characteristics were used to predict onset of TRD. Results: 35,246 people met eligibility and 7,098 (20.1%) met TRD criteria after an average of 402 days. Significant predictors of TRD included patient age, diagnosis of insomnia and hypertension, psychiatric office visits, nurse telephonic encounters, anticonvulsant medication use, suicidality, physician specialty associated with index prescription, total prescription drug claims, unique antidepressants attempted, and duration of untreated illness (the lag between diagnosis and index prescription). The final model achieved an area under the curve (AUC) = 0.83. Structured patient-generated health data, specifically, the Patient Health Questionnaire-2 and the Patient Health Questionnaire-9 were only reported for 542 patients (1.5%). Conclusions: TRD transition occurs after a prolonged treatment period, suggesting clinical inertia. Using data routinely available to integrated delivery networks and accountable care organizations, it is feasible to identify patients likely to qualify as treatment resistant. Monitoring risk factors may allow health systems to identify patients at risk for TRD earlier, potentially improving outcomes. Early identification of this at-risk population can allow for targeted resources for earlier intervention, more aggressive follow-up, and alternative treatment options. Furthermore, this model can be used to estimate future demand for specialized care resources, such as those delivered by mood disorder clinics. Disclosures: This project was sponsored by Janssen Scientific Affairs. Pesa, Chow, and Verbanac are employed by Janssen Scientific Affairs and report stock ownership in Johnson & Johnson. Liberman, Davis, Heverly-Fitt, and Ruetsch are employed by Health Analytics, which received funding from Janssen Scientific Affairs for work on this project. This study was presented as a poster at the U.S. Psych Congress; October 3-6, 2019; San Diego, CA.
Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study

Edward Millgate,Kira Griffiths,Alice Egerton,Eugenia Kravariti,Cecilia Casetta,Bill Deakin,Richard Drake,Oliver D Howes,Laura Kassoumeri,Sobia Khan,Steve Lankshear,Jane Lees,Shon Lewis,Elena Mikulskaya,Ebenezer Oloyede,Rebecca Owens,Rebecca Pollard,Nathalie Rich,Sophie Smart,Aviv Segev,Kyra Verena Sendt,James MacCabe

DOI: https://doi.org/10.1136/bmjopen-2022-062570

IF: 3.006

2022-11-22

BMJ Open

Abstract:Objectives This prospective cohort study tested for associations between baseline cognitive performance in individuals early within their first episode and antipsychotic treatment of psychosis. We hypothesised that poorer cognitive functioning at the initial assessment would be associated with poorer antipsychotic response following the subsequent 6 weeks. Design Prospective cohort . Setting National Health Service users with a first-episode schizophrenia diagnosis, recently starting antipsychotic medication, recruited from two UK sites (King's College London, UK and University of Manchester, UK). Participants attended three study visits following screening. Participants Eighty-nine participants were recruited, with 46 included in the main analysis. Participants required to be within the first 2 years of illness onset, had received minimal antipsychotic treatment, have the capacity to provide consent, and be able to read and write in English. Participants were excluded if they met remission criteria or showed mild to no symptoms. Primary and secondary outcome measures Antipsychotic response was determined at 6 weeks using the Positive and Negative Syndrome Scale (PANSS), with cognitive performance assessed at each visit using the Brief Assessment of Cognition in Schizophrenia (BACS). The groups identified (responders and non-responders) from trajectory analyses, as well as from >20% PANSS criteria, were compared on baseline BACS performance. Results Trajectory analyses identified 84.78% of the sample as treatment responsive, and the remaining 15.22% as treatment non-responsive. Unadjusted and adjusted logistic regressions observed no significant relationship between baseline BACS on subscale and total performance (BACS t-score: OR=0.98, p=0.620, Cohen's d=0.218) and antipsychotic response at 6 weeks. Conclusions This investigation identified two clear trajectories of treatment response in the first 6 weeks of antipsychotic treatment. Responder and non-responder groups did not significantly differ on performance on the BACS, suggesting that larger samples may be required or that an association between cognitive performance and antipsychotic response is not observable in the first 2 years of illness onset. Trial registration number REC: 17/NI/0209.

medicine, general & internal
S67. TREATMENT-RESISTANCE AFFECTS LONG-TERM COGNITIVE TRAJECTORIES IN SCHIZOPHRENIA: A LONGITUDINAL STUDY

Marco Spangaro,Marta Bosia,Margherita Bechi,Mariachiara Buonocore,Francesca Martini,Roberto Cavallaro

DOI: https://doi.org/10.1093/schbul/sbaa031.133

2020-04-01

Schizophrenia Bulletin

Abstract:Abstract Background Schizophrenia is a highly heterogeneous disorder, and despite extensive research progress approximately 30% of patients with schizophrenia show poor response to first-line antipsychotics, denoted as treatment-resistant schizophrenia (TRS). Meta-analytic evidence showed that clozapine is the most effective antipsychotic for TRS, although 40% of TRS patients do not respond even to clozapine (ultra-treatment-resistant schizophrenia -UTR). Recent studies indicated that TRS is neurobiologically and categorically distinct from treatment-responsive schizophrenia, being associated with elevated glutamate levels in the anterior cingulate cortex and unaltered striatal dopamine synthesis. Moreover, the striking majority of TRS patients do not respond to first-line antipsychotic therapy since disease onset and present more severe cognitive deficits since first episode of psychosis, further suggesting the presence of a distinct and more disrupted neurobiological substrate. It is widely known that cognitive impairment is a core feature of schizophrenia and determines a significant detrimental impact on long-term functional outcome, which represents the ultimate treatment goal. However, despite the central role of cognition in schizophrenia, to date no study has investigated longitudinal cognitive outcome among TRS patients. Based on these evidences, the aim of this study is to evaluate longitudinal cognitive trajectories in a sample of clinically stabilized patients with schizophrenia, stratified according to antipsychotic response. We hypothesized that treatment-resistance is associated with a more severe long-term cognitive decline. Methods We enrolled 93 patients with schizophrenia (DSM-V), stratified as follows: 32 first-line responders (FLR), 42 TRS and 19 UTR. Cognition was longitudinally assessed at baseline and at least after 6 years of follow-up (mean: 9.3±2.8 years) using the Brief Assessment of Cognition in Schizophrenia (BACS). From BACS subscores we calculated for each patient a Cognitive Index, as a measure of overall cognitive functioning. In order to quantify global cognitive functioning changes during the course of illness, we estimated effect size score for Cognitive Index using Cohen’s d. Finally, General linear Models (GLM) were performed with overall cognitive index effect size as dependent variable, treatment (FLR/TRS/UTR) as categorical variable and age, duration of illness and education as covariates. Results The first GLM (FLR vs TRS+UTR) showed a significant main effect of treatment (F=7.34, p=0.01), with worse cognitive outcome between resistant patients. Consistently, the second GLM (FLR/TRS/UTR) resulted significant as well (F=17.90, p<0.001), with UTR group showing worse cognitive trajectory (Fisher’s post-hoc: p<0.001, UTR Cognitive Index effect size = -0.7). Discussion This is the first study to longitudinally evaluate cognitive trajectories of patients with schizophrenia according to their antipsychotic response. We showed that treatment resistance is associated with a more severe cognitive decline, with worse outcome among UTR patients. These data suggest that greater severity of treatment resistance in schizophrenia is associated with greater cognitive impairment, possibly due to the presence of a distinct and more disrupted neurobiological substrate that affects both cognition and antipsychotic response. These findings further highlight the necessity of early individuation and tailored pharmacological treatment for TRS patients, in order to improve long-term clinical, cognitive and functional outcome.

psychiatry
Efficiently identifying individuals at high risk for treatment resistance in major depressive disorder using electronic health records

Isaac Lage,Thomas H McCoy,Roy H Perlis,Finale Doshi-Velez,Thomas H. McCoy Jr,Roy H. Perlis

DOI: https://doi.org/10.1016/j.jad.2022.02.046

IF: 6.533

2022-06-01

Journal of Affective Disorders

Abstract:BACKGROUND: With the emergence of evidence-based treatments for treatment-resistant depression, strategies to identify individuals at greater risk for treatment resistance early in the course of illness could have clinical utility. We sought to develop and validate a model to predict treatment resistance in major depressive disorder using coded clinical data from the electronic health record.METHODS: We identified individuals from a large health system with a diagnosis of major depressive disorder receiving an index antidepressant prescription, and used a tree-based machine learning classifier to build a risk stratification model to identify those likely to experience treatment resistance. The resulting model was validated in a second health system.RESULTS: In the second health system, the extra trees model yielded an AUC of 0.652 (95% CI: 0.623-0.682); with sensitivity constrained at 0.80, specificity was 0.358 (95% CI: 0.300-0.413). Lift in the top quintile was 1.99 (95% CI: 1.76-2.22). Including additional data for the 4 weeks following treatment initiation did not meaningfully improve model performance.LIMITATIONS: The extent to which these models generalize across additional health systems will require further investigation.CONCLUSION: Electronic health records facilitated stratification of risk for treatment-resistant depression and demonstrated generalizability to a second health system. Efforts to improve upon such models using additional measures, and to understand their performance in real-world clinical settings, are warranted.

psychiatry,clinical neurology
Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study

Lin Zhang,Aohan Bai,Zhongyu Tang,Xuebing Liu,Yi Li,Jun Ma

DOI: https://doi.org/10.3389/fpsyt.2023.1173263

IF: 4.7

2023-04-28

Frontiers in Psychiatry

Abstract:Background: Schizophrenia is a severe and persistent mental condition that causes disability. For subsequent clinical care, it is extremely practical to effectively differentiate between patients who respond to therapy quickly and those who do not. This study set out to document the prevalence and risk factors for patient early non-response. Methods: The current study included 143 individuals with first-treatment and drug-naïve (FTDN) schizophrenia. Patients were classified as early non-responders based on a Positive and Negative Symptom Scale (PANSS) score reduction of less than 20% after 2 weeks of treatment, otherwise as early responders. Clinical subgroups' differences in demographic data and general clinical data were compared, and variables related to early non-response to therapy were examined. Results: Two weeks later, a total of 73 patients were described as early non-responders, with an incidence of 51.05%. The early non-response subgroup had significantly higher PANSS scores, Positive symptom subscale (PSS) scores, General psychopathology subscale (GPS) scores, Clinical global impression scale - severity of illness (CGI-SI) and Fasting blood glucose (FBG) levels compared to the early-response subgroup. CGI-SI and FBG were risk factors for early non-response. Conclusion: High rates of early non-response have been seen in FTDN schizophrenia patients, and risk variables for predicting early non-response include CGI-SI scores and FBG levels. However, we need more in-depth studies to confirm the generalizable range of these two parameters.

psychiatry

Rangiferine Brucellosis in a Muskox, Ovibos moschatus moschatus (Zimmermann)

Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT)

Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

A predictor model of treatment resistance in schizophrenia using data from electronic health records

Early Treatment-Resistance in First Episode Psychosis

Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition

Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates

Apoptosis, necrosis and autophagy: from mechanisms to biomedical applications.

Neurodevelopmental predictors of treatment response in schizophrenia and bipolar disorder

Development of an individualized risk calculator of treatment resistance in patients with first-episode psychosis (TRipCal) using automated machine learning: a 12-year follow-up study with clozapine prescription as a proxy indicator

Subtyping First-Episode Psychosis based on Longitudinal Symptom Trajectories Using Machine Learning

Long-term clinical recovery and treatment resistance in first-episode psychosis: a 10-year follow-up study

Different Lifestyles and their Impact on the Environment

Tracking Positive and Negative Symptom Improvement in First-Episode Schizophrenia Treated with Risperidone Using Individual-Level Functional Connectivity

Psychosis Prognosis Predictor: A continuous and uncertainty‐aware prediction of treatment outcome in first‐episode psychosis

Association of U2, U4, U5, and U6 small nuclear ribonucleoproteins in a spliceosome-type complex in absence of precursor RNA.

Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Systems of Care

Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study

S67. TREATMENT-RESISTANCE AFFECTS LONG-TERM COGNITIVE TRAJECTORIES IN SCHIZOPHRENIA: A LONGITUDINAL STUDY

Efficiently identifying individuals at high risk for treatment resistance in major depressive disorder using electronic health records

Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study